Literature DB >> 9837747

Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF-kappaB activation.

E Sueoka1, N Sueoka, Y Kai, S Okabe, M Suganuma, K Kanematsu, T Yamamoto, H Fujiki.   

Abstract

We recently reported that morphine inhibits growth of various human cancer cell lines (IC50/2.7-8.8 mM). We then extended the study using newly synthesized morphine derivatives, such as KT-90 and KT-87, which are analgesics 5 times more potent than morphine. KT-90 was found to inhibit growth of human cancer cell lines (IC50/42-70 microM) up to 80 times more potently than morphine. As for mechanisms of action, KT-90 and morphine induced apoptosis, and inhibited tumor necrosis factor alpha (TNF-alpha) gene expression induced by tumor promoters, okadaic acid and 12-O-tetradecanoylphorbol-13-acetate, associated with reduction of NF-kappaB DNA binding activity. This paper provides evidence that KT compounds confirmed the presence of anticancer activity of morphine in addition to its analgesic action. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837747     DOI: 10.1006/bbrc.1998.9695

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Morphine as a treatment of cancer-induced pain-is it safe? A review of in vivo studies and mechanisms.

Authors:  David Brinkman; Jiang H Wang; Henry P Redmond
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-09-20       Impact factor: 3.000

2.  Morphine inhibits cell viability and growth via suppression of vascular endothelial growth factor in human oral cancer HSC-3 cells.

Authors:  Tadashi Nishiwada; Yoshitaka Kawaraguchi; Keiko Uemura; Masahiko Kawaguchi
Journal:  J Anesth       Date:  2019-05-02       Impact factor: 2.078

Review 3.  Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology.

Authors:  George B Stefano; Richard M Kream; Kirk J Mantione; Melinda Sheehan; Patrick Cadet; Wei Zhu; Thomas V Bilfinger; Tobias Esch
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

4.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer.

Authors:  Tamara King; Anna Vardanyan; Lisa Majuta; Ohannes Melemedjian; Ray Nagle; Anne E Cress; Todd W Vanderah; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2007-08-15       Impact factor: 6.961

Review 5.  The role of morphine in regulation of cancer cell growth.

Authors:  Katarzyna Gach; Anna Wyrębska; Jakub Fichna; Anna Janecka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

6.  Morphine use in cancer surgery.

Authors:  Banafsheh Afsharimani; Peter J Cabot; Marie-Odile Parat
Journal:  Front Pharmacol       Date:  2011-08-08       Impact factor: 5.810

7.  Chronic Opium Treatment Can Differentially Induce Brain and Liver Cells Apoptosis in Diabetic and Non-diabetic Male and Female Rats.

Authors:  Majid Asiabanha; Gholamreza Asadikaram; Amir Rahnema; Mehdi Mahmoodi; Gholamhosein Hasanshahi; Mohammad Hashemi; Mohammad Khaksari
Journal:  Korean J Physiol Pharmacol       Date:  2011-12-27       Impact factor: 2.016

8.  Receptorphin: a conserved peptide derived from the sequence of the opioid receptor, with opioid displacement activity and potent antiproliferative actions in tumor cells.

Authors:  M Kampa; S Loukas; A Tsapis; E Castanas
Journal:  BMC Pharmacol       Date:  2001-11-27

9.  μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer.

Authors:  Anna Cieślińska; Edyta Sienkiewicz-Szłapka; Elżbieta Kostyra; Ewa Fiedorowicz; Jadwiga Snarska; Konrad Wroński; Michał Tenderenda; Beata Jarmołowska; Michał Matysiewicz
Journal:  Tumour Biol       Date:  2015-01-25

10.  Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer.

Authors:  Dong-Ge Niu; Fei Peng; Wei Zhang; Zhong Guan; Hai-Dong Zhao; Jing-Lin Li; Kai-Li Wang; Ting-Ting Li; Yan Zhang; Fei-Meng Zheng; Fan Xu; Qian-Ni Han; Peng Gao; Qing-Ping Wen; Quentin Liu
Journal:  Oncotarget       Date:  2015-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.